2 completed, 1 terminated, 1 unknown. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Unknown 1 |
Follow Endocarditis, Bacterial: new trials by email Literature Review of Endocarditis, Bacterial trials Research Report on Endocarditis, Bacterial
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment - Drug Use, Opioid-use Disorder | Phase 2 | Completed | Laura Fanucchi | 71 | 2021-03-16 | 2026-04-28 |
| Hyperbaric Oxygen Treatment in Humans With Gram Positive Cocci Endocarditis Hyperbaric oxygen - Infectious Endocarditis | Phase 2 | Unknown | Ole Hyldegaard | 10 | 2019-12-01 | 2020-12-31 |
| Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis Ceftriaxone 4g/ 24h, Ceftriaxone 2g/ 12h - Infectious Endocarditis | Phase 2 | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 12 | 2018-04-23 | 2024-04-03 |
| Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia daptomycin, vancomycin - Endocarditis, Bacterial, Infective Endocarditis | Phase 2 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 38 | 2008-09-17 | 2018-12-24 |
Endocarditis, Subacute Bacterial (3) · Bacteremia (1) · Endocarditis (1) · Gram-Positive Bacterial Infections (1) · Infections (1) · Opioid-Related Disorders (1) · Staphylococcal Infections (1)
Bacterial Infections (4) · Bacterial Infections and Mycoses (4) · Cardiovascular Diseases (4) · Cardiovascular Infections (4) · Heart Diseases (4) · Endocarditis (3) · Gram-Positive Bacterial Infections (3) · Infections (3) · Streptococcal Infections (3) · Chemically-Induced Disorders (1) · Inflammation (1) · Mental Disorders (1) · Narcotic-Related Disorders (1) · Pathologic Processes (1)
Buprenorphine (1) · Buprenorphine, Naloxone Drug Combination (1) · Ceftriaxone (1) · Daptomycin (1) · Hyperbaric Oxygenation (1) · Injections (1) · Sublocade (1) · Vancomycin (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Laura Fanucchi (1) · Ole Hyldegaard (1)
United States (2) · Denmark (1) · Spain (1)
Ole Hyldegaard, MD, PHD (1) · Peter Pertel, MD (1)
2019 (1), R01DA048892 (1)